NASDAQ:SRRK Scholar Rock Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Scholar Rock Holding Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.17 +0.31 (+1.74 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$16.19Now: $18.17▼$18.1750-Day Range$11.29MA: $14.27▼$17.8652-Week Range$6.95Now: $18.17▼$21.92Volume208,901 shsAverage Volume116,425 shsMarket Capitalization$542.83 millionP/E RatioN/ADividend YieldN/ABeta0.79 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingScholar Rock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.00, Scholar Rock has a forecasted upside of 87.1% from its current price of $18.17.Amount of Analyst CoverageScholar Rock has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesScholar Rock has received 117 “outperform” votes. (Add your “outperform” vote.)Underperform VotesScholar Rock has received 137 “underperform” votes. (Add your “underperform” vote.)Community SentimentScholar Rock has received 53.94% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote “Outperform” if you believe SRRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldScholar Rock does not currently pay a dividend.Dividend GrowthScholar Rock does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scholar Rock insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 24.60% of the stock of Scholar Rock is held by insiders.Percentage Held by Institutions66.27% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Scholar Rock are expected to decrease in the coming year, from ($2.30) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scholar Rock is -8.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scholar Rock is -8.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScholar Rock has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRK Previous Symbol CUSIPN/A CIKN/A Webwww.scholarrock.com Phone857-259-3860Debt Debt-to-Equity Ratio0.04 Current Ratio4.46 Quick Ratio4.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.49 million Price / Sales26.49 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book4.78Profitability EPS (Most Recent Fiscal Year)($1.85) Net Income$-51,000,000.00 Net Margins-301.13% Return on Equity-61.68% Return on Assets-35.74%Miscellaneous Employees65 Outstanding Shares29,875,000Market Cap$542.83 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $18.17 +0.31 (+1.74 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SRRK News and Ratings via Email Sign-up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions How has Scholar Rock's stock been impacted by Coronavirus? Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SRRK stock has increased by 22.3% and is now trading at $18.17. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Scholar Rock? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Scholar Rock. When is Scholar Rock's next earnings date? Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Scholar Rock. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Corp (NASDAQ:SRRK) announced its quarterly earnings results on Friday, August, 7th. The company reported ($0.65) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.12. The firm had revenue of $3.90 million for the quarter, compared to analysts' expectations of $6.60 million. Scholar Rock had a negative return on equity of 61.68% and a negative net margin of 301.13%. View Scholar Rock's earnings history. What price target have analysts set for SRRK? 3 brokerages have issued 12-month price objectives for Scholar Rock's stock. Their forecasts range from $33.00 to $35.00. On average, they expect Scholar Rock's stock price to reach $34.00 in the next year. This suggests a possible upside of 87.1% from the stock's current price. View analysts' price targets for Scholar Rock. Who are some of Scholar Rock's key competitors? Some companies that are related to Scholar Rock include Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Revolution Medicines (RVMD), BAVARIAN NORDIC/S (BVNRY), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Coherus Biosciences (CHRS), Adaptimmune Therapeutics (ADAP), Compugen (CGEN), Atara Biotherapeutics (ATRA) and Regenxbio (RGNX). View all competitors. What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Coherus Biosciences (CHRS), Exelixis (EXEL), Nektar Therapeutics (NKTR), VBI Vaccines (VBIV), Atara Biotherapeutics (ATRA), CymaBay Therapeutics (CBAY), Cidara Therapeutics (CDTX) and Chiasma (CHMA). Who are Scholar Rock's key executives? Scholar Rock's management team includes the following people: Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)Mr. Yung H. Chyung, Chief Medical Officer (Age 43)Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)Ms. Catherine Hu, Exec. Director of Investor Relations & Corp. Communications When did Scholar Rock IPO? (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Scholar Rock's stock symbol? Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK." Who are Scholar Rock's major shareholders? Scholar Rock's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Bellevue Group AG (9.19%), Artal Group S.A. (8.45%), Federated Hermes Inc. (0.46%), Nuveen Asset Management LLC (0.42%) and Bank of New York Mellon Corp (0.28%). View institutional ownership trends for Scholar Rock. Which major investors are selling Scholar Rock stock? SRRK stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Russell Investments Group Ltd., Amia Capital LLP, and UBS Group AG. View insider buying and selling activity for Scholar Rock. Which major investors are buying Scholar Rock stock? SRRK stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Alps Advisors Inc., Canada Pension Plan Investment Board, California Public Employees Retirement System, Bellevue Group AG, Jacobs Levy Equity Management Inc., Nuveen Asset Management LLC, and Goldman Sachs Group Inc.. View insider buying and selling activity for Scholar Rock. How do I buy shares of Scholar Rock? Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Scholar Rock's stock price today? One share of SRRK stock can currently be purchased for approximately $18.17. How big of a company is Scholar Rock? Scholar Rock has a market capitalization of $542.83 million and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Scholar Rock employs 65 workers across the globe. What is Scholar Rock's official website? The official website for Scholar Rock is www.scholarrock.com. How can I contact Scholar Rock? Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
